[go: up one dir, main page]

WO2008096775A1 - 疼痛疾患治療剤 - Google Patents

疼痛疾患治療剤 Download PDF

Info

Publication number
WO2008096775A1
WO2008096775A1 PCT/JP2008/051920 JP2008051920W WO2008096775A1 WO 2008096775 A1 WO2008096775 A1 WO 2008096775A1 JP 2008051920 W JP2008051920 W JP 2008051920W WO 2008096775 A1 WO2008096775 A1 WO 2008096775A1
Authority
WO
WIPO (PCT)
Prior art keywords
pain
disease
neuropathy
agent
active ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/051920
Other languages
English (en)
French (fr)
Inventor
Yoshitaka Nakazawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Zoki Pharmaceutical Co Ltd
Original Assignee
Nippon Zoki Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Zoki Pharmaceutical Co Ltd filed Critical Nippon Zoki Pharmaceutical Co Ltd
Priority to KR1020097014813A priority Critical patent/KR101472431B1/ko
Priority to CN2008800039466A priority patent/CN101600438B/zh
Priority to US12/449,152 priority patent/US8492350B2/en
Priority to AU2008212250A priority patent/AU2008212250B2/en
Priority to CA2677026A priority patent/CA2677026C/en
Priority to EP08704491.3A priority patent/EP2119444B1/en
Publication of WO2008096775A1 publication Critical patent/WO2008096775A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7012—Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

　本発明はシアル酸又はその薬学的に許容される塩を有効成分として含有する非炎症性疼痛疾患に対する鎮痛剤に関するものである。本発明薬剤の有効成分であるシアル酸は、非炎症性疼痛である神経因性疼痛の病態モデル動物に対し鎮痛作用を示した。従って、本発明鎮痛剤は、例えば、三叉神経痛、帯状疱疹後神経痛、絞扼性神経障害、複合性局所痛症候群、糖尿病性ニューロパチー、外傷による神経障害、幻肢痛、脊髄損傷後や脳卒中後の中枢痛、並びに薬物療法や放射線療法によるニューロパチー等の神経因性疼痛疾患等の非炎症性疼痛疾患を治療するための薬剤として有用である。
PCT/JP2008/051920 2007-02-08 2008-02-06 疼痛疾患治療剤 Ceased WO2008096775A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
KR1020097014813A KR101472431B1 (ko) 2007-02-08 2008-02-06 동통질환 치료제
CN2008800039466A CN101600438B (zh) 2007-02-08 2008-02-06 疼痛疾病治疗剂
US12/449,152 US8492350B2 (en) 2007-02-08 2008-02-06 Therapeutic agent for pain disease
AU2008212250A AU2008212250B2 (en) 2007-02-08 2008-02-06 Therapeutic agent for pain disease
CA2677026A CA2677026C (en) 2007-02-08 2008-02-06 An analgesic composition for neuropathic pain diseases containing n-acetylneuraminic acid
EP08704491.3A EP2119444B1 (en) 2007-02-08 2008-02-06 Therapeutic agent for pain disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-028721 2007-02-08
JP2007028721A JP4005115B1 (ja) 2007-02-08 2007-02-08 疼痛疾患治療剤

Publications (1)

Publication Number Publication Date
WO2008096775A1 true WO2008096775A1 (ja) 2008-08-14

Family

ID=38769833

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051920 Ceased WO2008096775A1 (ja) 2007-02-08 2008-02-06 疼痛疾患治療剤

Country Status (9)

Country Link
US (1) US8492350B2 (ja)
EP (1) EP2119444B1 (ja)
JP (1) JP4005115B1 (ja)
KR (1) KR101472431B1 (ja)
CN (1) CN101600438B (ja)
AU (1) AU2008212250B2 (ja)
CA (1) CA2677026C (ja)
TW (1) TWI405576B (ja)
WO (1) WO2008096775A1 (ja)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116139A1 (en) * 2008-05-08 2009-11-11 Nestec S.A. Sialic acid to support brain health in the elderly
US20110301103A1 (en) * 2010-06-05 2011-12-08 Chugh Sumant S Methods of Treatment
US9867839B2 (en) 2012-05-14 2018-01-16 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US10028908B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9925203B2 (en) 2012-05-14 2018-03-27 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9943531B2 (en) 2014-08-08 2018-04-17 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US10028969B2 (en) 2012-05-14 2018-07-24 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9211257B2 (en) 2012-05-14 2015-12-15 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10463682B2 (en) 2012-05-14 2019-11-05 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating low back pain
US9700570B2 (en) 2014-05-27 2017-07-11 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956234B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for joint conditions
US9895383B2 (en) 2012-05-14 2018-02-20 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9999628B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9717747B2 (en) 2012-05-14 2017-08-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US10111837B2 (en) 2012-05-14 2018-10-30 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds
US9956238B2 (en) 2014-05-15 2018-05-01 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10413561B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US9844559B2 (en) 2012-05-14 2017-12-19 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesions
US10493085B2 (en) 2012-05-14 2019-12-03 Antecip Bioventures Ii Llc Neridronic acid and other bisphosphonates for treating complex regional pain syndrome and other diseases
US10092581B2 (en) 2014-05-15 2018-10-09 Antecip Bioventures Ii Llc Osteoclast inhibitors such as zoledronic acid for low back pain treatment
US9795622B2 (en) 2012-05-14 2017-10-24 Antecip Bioventures Ii Llc Neridronic acid for treating pain associated with a joint
US9999629B2 (en) 2012-05-14 2018-06-19 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10039773B2 (en) 2012-05-14 2018-08-07 Antecip Bioventures Ii Llc Neridronic acid for treating arthritis
US9820999B2 (en) 2012-05-14 2017-11-21 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9707247B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US10350227B2 (en) 2012-05-14 2019-07-16 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US10004756B2 (en) 2014-05-15 2018-06-26 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9827192B2 (en) 2012-05-14 2017-11-28 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US11654152B2 (en) 2012-05-14 2023-05-23 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating disease
US9789128B2 (en) 2012-05-14 2017-10-17 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10173986B2 (en) 2012-05-14 2019-01-08 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US10016445B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9949993B2 (en) 2012-05-14 2018-04-24 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating low back pain
US9877977B2 (en) 2012-05-14 2018-01-30 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9956237B2 (en) 2012-05-14 2018-05-01 Antecip Bioventures Ii Llc Osteoclast inhibitors for knee conditions
US9867840B2 (en) 2014-05-27 2018-01-16 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10034890B2 (en) 2012-05-14 2018-07-31 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US9707245B2 (en) 2012-05-14 2017-07-18 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9901589B2 (en) 2012-05-14 2018-02-27 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating complex regional pain syndrome
US10413560B2 (en) 2012-05-14 2019-09-17 Antecip Bioventures Ii Llc Dosage forms for oral administration of zoledronic acid or related compounds for treating disease
US9827256B2 (en) 2014-05-27 2017-11-28 Antecip Bioventures Ii Llc Compositions for administration of zoledronic acid or related compounds for treating lower back pain
US9861648B2 (en) 2012-05-14 2018-01-09 Antecip Boiventures Ii Llc Osteoclast inhibitors for knee conditions
US10080765B2 (en) 2012-05-14 2018-09-25 Antecip Bioventures Ii Llc Neridronic acid for treating complex regional pain syndrome
US9694023B2 (en) 2012-05-14 2017-07-04 Antecip Bioventures Ii Llc Methods for the safe administration of imidazole or imidazolium compounds
US9782421B1 (en) 2012-05-14 2017-10-10 Antecip Bioventures Ii Llc Neridronic acid molecular complex for treating complex regional pain syndrome
US10016446B2 (en) 2012-05-14 2018-07-10 Antecip Bioventures Ii Llc Compositions for oral administration of zoledronic acid or related compounds for treating Paget's disease of bone
US9770457B2 (en) 2012-05-14 2017-09-26 Antecip Bioventures Ii Llc Neridronic acid for treating bone marrow lesion
JP5275502B1 (ja) * 2012-10-10 2013-08-28 日本臓器製薬株式会社 抽出物及び製剤
CN103357006B (zh) * 2012-10-10 2014-10-15 日本脏器制药株式会社 含有提取物的制剂的检查方法
JP5490939B2 (ja) * 2013-04-19 2014-05-14 日本臓器製薬株式会社 抽出物及び製剤
JP5844320B2 (ja) * 2013-08-23 2016-01-13 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
JP5844338B2 (ja) * 2013-11-19 2016-01-13 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
US20140348916A1 (en) * 2014-08-11 2014-11-27 Antecip Bioventures Ii Llc Treatment of Pain with Oral Dosage Forms Comprising Zoledronic Acid and An Enhancer
JP6651466B2 (ja) * 2015-02-03 2020-02-19 敦子 森田 アナツバメ巣を原材料とする酵母発酵液、組成物及び素材の製造方法
JP6043922B2 (ja) * 2015-11-20 2016-12-14 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
KR101873527B1 (ko) 2016-09-02 2018-07-02 부산대학교 산학협력단 시알산 유도체를 포함하는 자궁내막증 예방 또는 치료용 조성물
JP2016216518A (ja) * 2016-09-28 2016-12-22 日本臓器製薬株式会社 抽出物及び該抽出物を含有する製剤
SE541422C2 (en) 2018-01-30 2019-09-24 Scania Cv Ab A method and an apparatus for controlling shifting of a transmission in a motor vehicle

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5234912A (en) * 1975-08-13 1977-03-17 Fidia Spa Extraction of ganglioside and application of same to new medicines
JPS62145015A (ja) 1985-12-19 1987-06-29 Kotobuki Chem:Kk 抗炎症剤
JPS6328411B2 (ja) 1984-09-11 1988-06-08 Mekuto Kk
JPH01157995A (ja) * 1987-11-02 1989-06-21 Fidia Spa 鎮痛−抗炎症活性を有するガングリオシドの内部エステル
JPH01163125A (ja) 1987-12-21 1989-06-27 Shiseido Co Ltd 抗炎症剤
JPH05105694A (ja) * 1991-03-06 1993-04-27 Nippon Zoki Pharmaceut Co Ltd シアル酸誘導体
JPH09301874A (ja) * 1996-05-16 1997-11-25 Snow Brand Milk Prod Co Ltd 脳機能改善剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476119A (en) * 1981-08-04 1984-10-09 Fidia S.P.A. Method for preparing ganglioside derivatives and use thereof in pharmaceutical compositions
US5438125A (en) * 1991-03-06 1995-08-01 Nippon Zoki Pharmaceutical Co., Ltd. Sialic acid derivatives
IT1260156B (it) * 1992-08-03 1996-03-28 Fidia Spa Derivati dell'acido neuraminico
CA2195863C (en) * 1995-05-25 2001-04-17 Michio Ohta Therapeutic drug for endotoxin blood symptom and multi-organ failure induced thereby
CN100400051C (zh) 2004-12-15 2008-07-09 阿尔贝拉医药控股(通化)有限公司 一种药物组合物、其制备方法及其用途
CN1305489C (zh) * 2005-08-10 2007-03-21 贵州老来福药业有限公司 一种治疗风寒湿痹的中药伤湿贴及其制备方法
CN1762486A (zh) 2005-10-28 2006-04-26 诺氏制药（吉林）有限公司 脑苷肌肽在制备防治周围神经疾病药物中的用途
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5234912A (en) * 1975-08-13 1977-03-17 Fidia Spa Extraction of ganglioside and application of same to new medicines
JPS6328411B2 (ja) 1984-09-11 1988-06-08 Mekuto Kk
JPS62145015A (ja) 1985-12-19 1987-06-29 Kotobuki Chem:Kk 抗炎症剤
JPH01157995A (ja) * 1987-11-02 1989-06-21 Fidia Spa 鎮痛−抗炎症活性を有するガングリオシドの内部エステル
JPH01163125A (ja) 1987-12-21 1989-06-27 Shiseido Co Ltd 抗炎症剤
JPH05105694A (ja) * 1991-03-06 1993-04-27 Nippon Zoki Pharmaceut Co Ltd シアル酸誘導体
JPH09301874A (ja) * 1996-05-16 1997-11-25 Snow Brand Milk Prod Co Ltd 脳機能改善剤

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
(AERBEILA MEDICINE HOLDINGS TONGHUA CO., LTD., PEOP. REP. CHINA), 9 August 2006 (2006-08-09) *
(LOKIS PHARMACEUTICAL (JILIN) CO., LTD., PEOP. REP. CHIA), 26 April 2006 (2006-04-26) *
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, vol. 114, no. 2, 1972, pages 190 - 193 *
CARLSON S.E. ET AL.: "Oral and Intraperitoneal Administration of N-Acetylneuraminic Acid: Effect on Rat Cerebral and Cerebellar N-Acetylneuraminic Acid", J. NUTR., vol. 116, no. 5, 1986, pages 881 - 886, XP008115096 *
CHAPLAN ET AL., J. NEUROSCI. METHOD, vol. 53, 1994, pages 55 - 63
DATABASE CAPLUS [online] OSTER G. ET AL.: "Cyclic variation of sialic acid content in saliva", XP008111846, accession no. STN Database accession no. (1972:562281) *
DATABASE CAPLUS [online] XP008111847, accession no. STN Database accession no. (2006:407679) *
DATABASE CAPLUS [online] XP008111848, accession no. STN Database accession no. (2006:803423) *
KIM; CHUNG, PAIN, vol. 50, 1992, pages 355 - 363
MORGAN B.L.G. ET AL.: "Effects of Administration of N-Acetylneuraminic Acid NANA on Brain NANA Content and Behavior", J. NUTR., vol. 110, no. 3, 1980, pages 416 - 424, XP009077464 *
See also references of EP2119444A4

Also Published As

Publication number Publication date
CA2677026A1 (en) 2008-08-14
US8492350B2 (en) 2013-07-23
KR20090107500A (ko) 2009-10-13
EP2119444A1 (en) 2009-11-18
KR101472431B1 (ko) 2014-12-12
CA2677026C (en) 2014-11-18
AU2008212250A1 (en) 2008-08-14
JP2008189635A (ja) 2008-08-21
JP4005115B1 (ja) 2007-11-07
TW200838545A (en) 2008-10-01
US20100121040A1 (en) 2010-05-13
EP2119444B1 (en) 2015-07-08
EP2119444A4 (en) 2010-06-09
TWI405576B (zh) 2013-08-21
CN101600438A (zh) 2009-12-09
AU2008212250B2 (en) 2013-07-04
CN101600438B (zh) 2012-06-27

Similar Documents

Publication Publication Date Title
WO2008096775A1 (ja) 疼痛疾患治療剤
AR058679A1 (es) Preparacion farmaceutica que contiene meloxicam
WO2006072589A3 (en) Disubstituted ureas as kinase inhibitors
WO2011014255A8 (en) Treatment of crohn's disease with laquinimod
BRPI1011220A2 (pt) composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada.
FI3287124T3 (fi) Ketamiinin oraalinen annosmuoto
MY140826A (en) Substituted pyrazoline compounds, their preparation and use as medicaments.
BRPI0807285A2 (pt) "composição, método para preparar composição farmacêutica, forma unitária de dosagem, método para admnistrar um agente biologicamente ativo a um animal necessitando o agente, método para aumentar a biodisponibilidade de um agente biologicamente ativo, método para preparar uma composição e composto"
MX2012000275A (es) Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal.
WO2013048558A3 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs
AR060019A1 (es) Composicion farmaceutica, producto y metodo de tratamiento para un trastorno cognitivo y usos de un inhibidor de acetilcolinesterasa y un antagonista de 5- ht6 en la fabricacion de un medicamento para el tratamiento de un trastorno cognitivo
NZ605469A (en) Nalbuphine-based formulations and uses thereof
WO2008149802A1 (ja) アンドログラホリドを有効成分とする抗疲労剤及び経口組成物
WO2008105507A1 (ja) 脊髄損傷治療薬剤
EP4464375A3 (en) Methods of treatment using single doses of oritavancin
EP2316420A8 (en) Method to reduce pain
MX2012008509A (es) Agente terapeutico o profilactic para enfermedades del tracto biliar.
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
WO2009003694A3 (en) Method for treating diseases related to mitochondrial dysfunction
WO2007009720A3 (en) Prodrugs of pyrazoline compounds, their preparation and use as medicaments
WO2008008882A3 (en) Glucocorticoid receptor modulator and methods of use
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
WO2010136035A3 (en) Novel calcium sensing receptor modulating compounds and pharmaceutical use thereof
BR112012022944A2 (ja) The medical treatment agent or prevention agent of a urine collection obstacle

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880003946.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704491

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 1020097014813

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2677026

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008212250

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008704491

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008212250

Country of ref document: AU

Date of ref document: 20080206

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12449152

Country of ref document: US